Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
Dados Bibliográficos
BACKGROUND: A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly vaccinated populations has aroused concerns about the effectiveness of current vaccines. METHODS: We used a test-negative case-control design to estimate vaccine effectiveness against symptomatic disease caused by the omicron and delta (B.1.617.2) variants in England. Vaccine effectiveness was calculated after primary immunization with two doses of BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca), or mRNA-1273 (Moderna) vaccine and after a booster dose of BNT162b2, ChAdOx1 nCoV-19, or mRNA-1273. RESULTS: Between November 27, 2021, and January 12, 2022, a total of 886,774 eligible persons infected with the omicron variant, 204,154 eligible persons infected with the delta variant, and 1,572,621 eligible test-negative controls were identified. At all time points investigated and for all combinations of primary course and booster vaccines, vaccine effectiveness against symptomatic disease was higher for the delta variant than for the omicron variant. No effect against the omicron variant was noted from 20 weeks after two ChAdOx1 nCoV-19 doses, whereas vaccine effectiveness after two BNT162b2 doses was 65.5% (95% confidence interval [CI], 63.9 to 67.0) at 2 to 4 weeks, dropping to 8.8% (95% CI, 7.0 to 10.5) at 25 or more weeks. Among ChAdOx1 nCoV-19 primary course recipients, vaccine effectiveness increased to 62.4% (95% CI, 61.8 to 63.0) at 2 to 4 weeks after a BNT162b2 booster before decreasing to 39.6% (95% CI, 38.0 to 41.1) at 10 or more weeks. Among BNT162b2 primary course recipients, vaccine effectiveness increased to 67.2% (95% CI, 66.5 to 67.8) at 2 to 4 weeks after a BNT162b2 booster before declining to 45.7% (95% CI, 44.7 to 46.7) at 10 or more weeks. Vaccine effectiveness after a ChAdOx1 nCoV-19 primary course increased to 70.1% (95% CI, 69.5 to 70.7) at 2 to 4 weeks after an mRNA-1273 booster and decreased to 60.9% (95% CI, 59.7 to 62.1) at 5 to 9 weeks. After a BNT162b2 primary course, the mRNA-1273 booster increased vaccine effectiveness to 73.9% (95% CI, 73.1 to 74.6) at 2 to 4 weeks; vaccine effectiveness fell to 64.4% (95% CI, 62.6 to 66.1) at 5 to 9 weeks. CONCLUSIONS: Primary immunization with two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccine provided limited protection against symptomatic disease caused by the omicron variant. A BNT162b2 or mRNA-1273 booster after either the ChAdOx1 nCoV-19 or BNT162b2 primary course substantially increased protection, but that protection waned over time. (Funded by the U.K. Health Security Agency.).
Booster (rocketry) · Disease · Immunization · Infectious disease (medical specialty) · Vaccination · Respiratory viral infections research · SARS-CoV-2 and COVID-19 Research · Vaccine Coverage and Hesitancy
Increased Secondary Attack Rates among the Household Contacts of Patients with the Omicron Variant of the Coronavirus Disease 2019 in Japan
Covid-19 Infection and Vaccination Among Healthcare Workers in a South African Academic Hospital
Community members have more impact on their neighbors than celebrities”
The impact of quality-adjusted life years on evaluating Covid-19 mitigation strategies
Factors That Affect the Covid-19 Pandemic in Summer 2022 Compared to Summer 2021
Panic in the Pandemic
Assessment of Sars-CoV-2 neutralizing antibody persistence using LFIC
Correlates of Covid-19 vaccination intentions and opinions about mandates among four groups of adults in South Africa with distinct vaccine intentions
How Did the Covid-19 Pandemic Affect Population Mobility in Taiwan
Delta and Omicron
Bibliometric Analysis of Global Scientific Production on Covid-19 and Vaccines
Social participation and mental health of immunocompromised individuals before and after Covid-19 vaccination–Results of a longitudinal observational study over three time points
Effectiveness of Booster Vaccinations on the Control of Covid-19 during the Spread of Omicron Variant in Malaysia
The role of vaccine status homophily in the Covid-19 pandemic
Acceptance of Seasonal Influenza Vaccine Following Covid-19 Vaccination
Studying Disease Reinfection Rates, Vaccine Efficacy, and the Timing of Vaccine Rollout in the Context of Infectious Diseases
STEM education in the Global North and Global South
Case study of the Beijing 2022 Olympic Winter Games
Policies on children and schools during the Sars-CoV-2 pandemic in Western Europe
Omicron Covid-19 variant outcomes and vaccination in non-severe and non-critical patients at admission
Critical national response in coping with Omicron variant in China, Israel, South Africa, and the United States
How to control the spatiotemporal spread of Omicron in the region with low vaccination rates
Is Endemicity a Solution for the Covid-19 Pandemic? The Four E's Strategy for the Public Health Leadership
Covid-19 vaccine response and safety in patients with cancer
Primary healthcare workers’ Covid-19 infection status following implementation of adjusted epidemic prevention and control strategies
Policy choices for Shanghai responding to challenges of Omicron
Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated Covid-19 vaccine
Assessing Vaccination Prioritization Strategies for Covid-19 in South Africa Based on Age-Specific Compartment Model
Willingness and Perceptions Regarding Covid-19 Vaccine Booster Dose in Pakistani Vaccinated Population
Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection
An exploration on Covid-19 vaccination motivation patterns from the perspective of the Chaxu culture in metropolis of China
Exploring attitudes toward Covid-19 vaccinations amongst healthcare workers at a national infectious disease center in Singapore—a cross-sectional study
Understanding spatiotemporal symptom onset risk of Omicron BA.1, BA.2 and hamster-related Delta AY.127
Frequency of Sars-CoV-2 variants identified by real-time PCR in the Auna healthcare network, Peru
Vaccine efficacy against Sars-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines
The role of booster vaccination in decreasing Covid-19 age-adjusted case fatality rate
Mathematical modeling of Sars-CoV-2 variant substitutions in European countries
Relationships between Covid-19 healthcare outcomes and county characteristics in the U.S. for Delta (B.1.617.2) and Omicron (B.1.1.529 and BA.1.1) variants
Adherence to Covid-19 preventive measures in Sub-Saharan Africa during the 1st year of the pandemic
The Vaccine Efficacy Against the Sars-CoV-2 Omicron
Willingness to vaccinate among adults, and factors associated with vaccine acceptance of Covid-19 vaccines in a nationwide study in Poland between March 2021 and April 2022
The pattern from the first three rounds of vaccination
Two years of Covid-19 pandemic
Effectiveness of Sars-CoV-2 vaccines against Omicron infection and severe events
Covid-19 vaccination roll-outs in eleven small countries within the WHO European region; Lessons learned
Perceptions and responses to Covid-19 through wastewater surveillance information and online search behavior
Mitigation strategies for responding to the Covid-19 pandemic after reopening from the global perspective
Factors, enablers and challenges for Covid-19 vaccine development
The compound risk of heat and Covid-19 in New York City
Social media narratives can influence vaccine intentions
Vaccine mandates for healthcare workers beyond Covid-19
Covid-19 vaccine boosters for young adults
Vaccination decisions under risk
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
A half-century investigation of police officer line-of-duty deaths
Can vaccination intentions against Covid-19 be nudged
Social Network, Trust, Approval of President Biden, Risk Perception, and Annual Covid-19 Booster Intention
Navigating Covid-19 Surges
Post-truth and pathways for evaluators
See That Post, Get That Shot
Disparities and effectiveness of Covid-19 vaccine policies in three representative European countries
Path dependency of urban resilience to recurring Covid-19 waves
Impact of the Covid-19 vaccination on confusion around vaccination in general
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa
Investigation of Covid-19 transmission during the first community outbreak in a remote island population, Falkland Islands, April to June 2022
Modelling Covid-19 vaccine breakthrough infections in highly vaccinated Israel—The effects of waning immunity and third vaccination dose
The economic impacts of Covid-19 hospitalizations, intensive care unit admissions, and deaths related to overweight and obesity
Moral characteristics predicting Covid ‐19 vaccination
Contextual Pathways Linking Cumulative Experiences of Racial Discrimination to Black American Men’s Covid Vaccine Hesitancy
Crises and complexity
A comparative study of eight Covid-19 protective measures and their impact on Swiss tourists’ travel intentions
The Impact of Urban Scaling Structure on the Local-Scale Transmission of Covid-19
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against Sars-CoV-2
Efficacy and Safety of the mRNA-1273 Sars-CoV-2 Vaccine
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
| Obras citantes distintas | 72 |
|---|---|
| Citações por ano | 18 |
| Intervalo de citações | 2022 - 2026 (5) |
| Velocidade de citação | current |
| Altamente citado | Não |
| Tipos de citação | Neutras: 70 |